10.75 USD
↗ 0.43 (4.17%)AT CLOSE (11:59 AM EDT)
Artiva Biotherapeutics, Inc. Common Stock
ARTVNASDAQ • USD
10.11
↘ 0.64 (5.95%)
POST MARKET (AS OF 06:06 PM EDT)
Post Market
AS OF 06:06 PM EDT
10.11
↘ 0.64 (5.95%)
Market: CLOSED
Open?$10.18
High?$11.37
Low?$10.01
Prev. Close?$10.32
Volume?133.1K
Avg. Volume?274.4K
VWAP?$10.82
Rel. Volume?0.49x
Bid / Ask
Bid?$10.11 × 100
Ask?$10.78 × 100
Spread?$0.67
Midpoint?$10.45
Valuation & Ratios
Market Cap?265.7M
Shares Out?24.7M
Float?4.0M
Float %?16.4%
P/E Ratio?N/A
P/B Ratio?2.42
EPS?-$3.39
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?8.61Strong
Quick Ratio?8.61Strong
Cash Ratio?2.04Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?N/A▾
P/B?2.42CHEAP▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-2.7CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-76.3%WEAK▾
ROA?-64.1%WEAK▾
Cash Flow & Enterprise
FCF?$-79338000
Enterprise Value?$239.0M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Employees
104
Market Cap
255.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2024-07-19
Address
5505 MOREHOUSE DRIVE
SAN DIEGO, CA 92121
Phone: (858) 267-4467
SAN DIEGO, CA 92121
Phone: (858) 267-4467